Female, %
|
60
|
52
|
68
|
60
|
67
|
55
|
Age at index, years, median (range)
|
39.0 (21–70)
|
38.0 (18–72)
|
42.0 (20–73)
|
40.5 (21–58)
|
41.0 (20–73)
|
39.0 (18–72)
|
CD duration, years, median (range) [n with available data]a
|
8.2 (0–30) [10]
|
3.7 (0–50) [65]
|
10.1 (1–35) [58]
|
7.2 (0–33) [40]
|
9.8 (0–35) [68]
|
5.6 (0–50) [105]
|
CD location, [n]
|
[9]
|
[57]
|
[57]
|
[34]
|
[66]
|
[91]
|
Ileal, %
|
22
|
18
|
26
|
24
|
26
|
20
|
Colonic, %
|
33
|
28
|
23
|
15
|
24
|
23
|
Ileocolonic, %
|
44
|
54
|
51
|
62
|
50
|
57
|
Disease behavior, [n]
|
[9]
|
[60]
|
[52]
|
[34]
|
[61]
|
[94]
|
Non-stricturing, non-penetrating, %
|
44
|
65
|
67
|
38
|
64
|
55
|
Stricturing, %
|
44
|
22
|
21
|
41
|
25
|
29
|
Penetrating, %
|
11
|
13
|
12
|
21
|
11
|
16
|
Prior IBD-related surgery, %
|
20
|
35
|
42
|
45
|
39
|
39
|
HBI score, [n]
|
[3]
|
[10]
|
[10]
|
[13]
|
[13]
|
[23]
|
0–4 (remission), %
|
33
|
40
|
30
|
46
|
31
|
43
|
5–7 (mild activity), %
|
33
|
60
|
30
|
15
|
31
|
35
|
8–16 (moderate activity), %
|
33
|
0
|
40
|
38
|
38
|
22
|
≥ 17 (severe activity), %
|
0
|
0
|
0
|
0
|
0
|
0
|
Abdominal pain score, [n]
|
[5]
|
[46]
|
[36]
|
[22]
|
[41]
|
[68]
|
0 (none), %
|
20
|
39
|
25
|
41
|
24
|
40
|
1 (mild), %
|
0
|
20
|
19
|
18
|
17
|
19
|
2 (moderate), %
|
80
|
37
|
47
|
27
|
51
|
34
|
3 (severe), %
|
0
|
4
|
8
|
14
|
7
|
7
|
Liquid/soft stools per day, mean (SD) [n]
|
3.7 (2.5) [3]
|
3.6 (3.8) [35]
|
5.2 (4.9) [26]
|
3.8 (4.7) [21]
|
5.0 (4.7) [29]
|
3.7 (4.1) [56]
|
Endoscopic score, [n]
|
[6]
|
[39]
|
[30]
|
[26]
|
[36]
|
[65]
|
0 (normal or inactive disease), %
|
17
|
10
|
27
|
27
|
25
|
17
|
1 (mild disease), %
|
17
|
21
|
20
|
19
|
19
|
20
|
2 (moderate disease), %
|
33
|
46
|
20
|
23
|
22
|
37
|
3 (severe disease), %
|
33
|
23
|
33
|
31
|
33
|
26
|
Corticosteroids in past 2 years, %
|
60
|
69
|
58
|
53
|
58
|
63
|
Aminosalicylates in past 2 years, %
|
20
|
37
|
31
|
45
|
29
|
40
|
Immunomodulators in past 2 years, %
|
20
|
57
|
29
|
48
|
28
|
53
|
Duration of previous anti-TNFα treatment, months, mean (SD), [n]
|
–
|
–
|
31.6 (24.3) [52]
|
22.3 (20.7) [39]
|
31.6 (24.3) [52]
|
22.3 (20.7) [39]
|
Duration from prior anti-TNFα discontinuation to index date, months, median (range), [n]
|
–
|
–
|
1.1 (0–103) [57]
|
2.1 (0–57) [39]
|
1.1 (0–103) [57]
|
2.1 (0–57) [39]
|
Index treatment, anti-TNFα type
|
Infliximab originator, %
|
–
|
42
|
–
|
45
|
–
|
43
|
Infliximab biosimilar, %
|
–
|
18
|
–
|
20
|
–
|
19
|
Adalimumab, %
|
–
|
40
|
–
|
35
|
–
|
38
|
Concomitant therapy at index
|
Corticosteroids, %
|
20
|
25
|
29
|
28
|
28
|
26
|
Immunomodulators, %
|
10
|
19
|
8
|
18
|
9
|
18
|
Aminosalicylates, %
|
0
|
14
|
15
|
20
|
13
|
16
|